Switch theme
Sign up to access all valuation multiples
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Planet, Investments, and others. The majority of its revenue is generated from the planet segment. The geographical segments are UAE, Other GCC countries, and Other countries.
1980
2.3K+
LTM Revenue $363M
LTM EBITDA $48.0M
$453M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Julphar has a last 12-month revenue (LTM) of $363M and a last 12-month EBITDA of $48.0M.
In the most recent fiscal year, Julphar achieved revenue of $357M and an EBITDA of $61.6M.
Julphar expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Julphar valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $363M | XXX | $357M | XXX | XXX | XXX |
| Gross Profit | $363M | XXX | $141M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $48.0M | XXX | $61.6M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $18.1M | XXX | $19.8M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $17.0M | XXX | $12.1M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $208M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Julphar's stock price is AED 1 (or $0).
Julphar has current market cap of AED 1.6B (or $425M), and EV of AED 1.7B (or $453M).
See Julphar trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $453M | $425M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Julphar has market cap of $425M and EV of $453M.
Julphar's trades at 1.3x EV/Revenue multiple, and 7.4x EV/EBITDA.
Equity research analysts estimate Julphar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Julphar has a P/E ratio of 25.0x.
See valuation multiples for Julphar and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $425M | XXX | $425M | XXX | XXX | XXX |
| EV (current) | $453M | XXX | $453M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBIT | 25.0x | XXX | 22.9x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.0x | XXX | 35.0x | XXX | XXX | XXX |
| EV/FCF | 15.5x | XXX | 8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJulphar's last 12 month revenue growth is 4%
Julphar's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Julphar's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Julphar's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Julphar and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Julphar acquired XXX companies to date.
Last acquisition by Julphar was XXXXXXXX, XXXXX XXXXX XXXXXX . Julphar acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Julphar founded? | Julphar was founded in 1980. |
| Where is Julphar headquartered? | Julphar is headquartered in United Arab Emirates. |
| How many employees does Julphar have? | As of today, Julphar has 2.3K+ employees. |
| Is Julphar publicy listed? | Yes, Julphar is a public company listed on ADS. |
| What is the stock symbol of Julphar? | Julphar trades under JULPHAR ticker. |
| When did Julphar go public? | Julphar went public in 2002. |
| Who are competitors of Julphar? | Similar companies to Julphar include e.g. Galapagos, Pharming, Vivoryon Therapeutics, Armata Pharmaceuticals. |
| What is the current market cap of Julphar? | Julphar's current market cap is $425M |
| What is the current revenue of Julphar? | Julphar's last 12 months revenue is $363M. |
| What is the current revenue growth of Julphar? | Julphar revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Julphar? | Current revenue multiple of Julphar is 1.2x. |
| Is Julphar profitable? | Yes, Julphar is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Julphar? | Julphar's last 12 months EBITDA is $48.0M. |
| What is Julphar's EBITDA margin? | Julphar's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Julphar? | Current EBITDA multiple of Julphar is 9.4x. |
| What is the current FCF of Julphar? | Julphar's last 12 months FCF is $29.3M. |
| What is Julphar's FCF margin? | Julphar's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Julphar? | Current FCF multiple of Julphar is 15.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
